Pjanova D, Heisele O, Engele L, Randerson-Moor JA, Harland M, Bishop DT, Newton Bishop JA, Taylor C, Debniak T, Lubinski J, Kleina R.
CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
Melanoma Res. 2007; 17 (3): 185-192.

Pjanova D, Heisele O, Engele L, Randerson-Moor JA, Kukalizch K, Bishop DT, Newton Bishop JA.
Analysis of Latvian melanoma families for 9p21 germline deletions by multiplex ligation-dependent probe amplification approach.
Acta Universitatis Latviensis. 2006; 710: 7-16.

Pjanova D, Engele L, Ignatovica V and Heisele O.
CDKN2A mutations and loss of heterozygosity in primary melanomas.
Proc. Latvian Acad. Sci. Section B. 2006; 60 (2/3): 98-100.

Pjanova D, Heisele O, Engele L, Desjatnikova I.
Tumour suppressor gene CDKN2A/p16 germline mutations in melanoma patients with additional cancer and cancer in their family history.
Acta Universitatis Latviensis. 2003, 662: 25-32.

Heisele O, Ferdats A, Engele L, Rupais A, Desjatnikova I.
Melanoma associated antigens as markers for melanoma progression and efficiacy of immunotherapy.
J.Tumour Marker Oncology. 2000, 15: 147-153.

Heisele O, Ferdats A, Engele L.
Melanoma associated antigens as additional markers of tumour progression.
J.Tumour Marker Oncology, 2000, 15: 147-153.

Pjanova D, Heisele O, Engele L, Balkovska I, Desjatnikova I, Ignatovica V.
CDKN2A/ARF and CDK4 germline alterations in sporadic cutaneous malignant melanoma patients of Latvian population.
In press.

Click here to see a PDF of this publication